A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy
Lay Description
Category
- Urinary Tract and Kidney
- IRB Number
- 20220600HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Not set
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Andrea Hansis-diarte
+1 (210) 617-5300
hansisdiarte@uthscsa.edu
Italia Herrera
(210) 567-2687
herrerai1@uthscsa.edu
Johnnie Jones
(210) 450-7277
jonesj21@uthscsa.edu
Subrata Debnath
(210) 508-2889
nath@uthscsa.edu
Lorannys Sanchez Tamarez
(210) 450-8332
sancheztamar@uthscsa.edu
Principal Investigator
Kumar Sharma